Roivant Sciences Ltd. Common Shares

ROIVNASDAQ • USD
38.70 USD
↗ 0.09 (0.22%)🟢PRE MARKET (AS OF 04:02 AM EST)
🟢Market: OPEN

Roivant Sciences Ltd. Common Shares (ROIV) trades at $38.70 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 16, 2026.

Open?$38.70
High?$38.70
Low?$38.70
Prev. Close?$38.61
Volume?100
Avg. Volume?7.6M
VWAP?$38.70
Rel. Volume?0.00x
Bid / Ask
Bid?$36.62 × 100
Ask?$41.05 × 100
Spread?$4.43
Midpoint?$38.83
Valuation & Ratios
Market Cap?28.0B
Shares Out?724.6M
Float?502.5M
Float %?69.6%
P/E Ratio?N/A
P/B Ratio?6.96
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
28.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
40
Short Sent.?
49
Piotroski F-Score?1/9Weak
Altman Z-Score?44.45Safe
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.06%Elevated
Short Interest?45.5M
Days to Cover?6.1
Free Float502.5M
Avg Daily Volume7.5M
Settlement Date2026-10-30
Financial Health
Current Ratio?15.56Strong
Quick Ratio?15.56Strong
Cash Ratio?5.87Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
27
6.96FAIR▾
P/S?
Peers
100
S&P
3
680.96HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-19.9CHEAP▾
EV/Sales?
Peers
100
S&P
3
640.99HIGH▾
Returns & Efficiency
ROE?
S&P
10
-8.6%WEAK▾
ROA?
S&P
3
-6.9%WEAK▾
Cash Flow & Enterprise
FCF?$-39435000
Enterprise Value?$26.3B
Fundamentals ratios updated end of day